AbelZeta - About the company
AbelZeta is a funded company based in Rockville (United States), founded in 2009. It operates as a Developer of T cell-based therapeutics for cancer and immunological diseases. The company has 3669 active competitors, including 1216 funded and 839 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Kite Pharma.
Company Details
Developer of T cell-based therapeutics for cancer and immunological diseases. The company leverages chimeric antigen receptor and T-cell tumor infiltrating lymphocytes to develop a diverse pipeline targeting cancer, inflammatory, and immunological diseases.
- Website
- www.abelzeta.com/
- Email ID
- *****@abelzeta.com
- Phone Number
- +1 **********
Key Metrics
Founded Year
2009
Location
Rockville, United States
Stage
Funding Raised
Investors
Ranked
747th among 3669 active competitors
Employee Count
115 as on Sep 30, 2026
Sign up to download AbelZeta's company profile
AbelZeta's funding and investors
AbelZeta is a funded company. AbelZeta has 2 institutional investors.
View details of AbelZeta's funding rounds and investors
AbelZeta's founders and board of directors
Founder? Claim ProfileAbelZeta's employee count trend
AbelZeta has 115 employees as of Sep 26. Here is AbelZeta's employee count trend over the years:
Uncover AbelZeta's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
AbelZeta's Competitors and alternates
Top competitors of AbelZeta include Jazz Pharmaceuticals, BeiGene and Kite Pharma. Here is the list of Top 10 competitors of AbelZeta, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Jazz Pharmaceuticals 2003, Dublin (Ireland), Public | Developer of novel biopharmaceutical medicines for unmet medical needs | $265M | 82/100 | |
2nd |  BeiGene 2010, Cambridge (United States), Public | Developer of targeted and immune-oncology drugs against cancer | $172M | 77/100 | |
3rd | Kite Pharma 2009, Los Angeles (United States), Acquired | Developer of cancer immunotherapy products using genetic engineering | $97.7M | 76/100 | |
4th |  Attovia 2023, Fremont (United States), Public | Developer of antibody-based therapeutics for immune-mediated diseases and oncology | $255M | 72/100 | |
5th |  Tango Therapeutics 2017, Cambridge (United States), Public | Developer of drugs for the treatment of cancer | $165M | 72/100 | |
6th |  Elicio 2012, Cambridge (United States), Public | Developer of vaccines for treating cancer | $47.4M | 72/100 | |
7th | Developer of T-cell therapies for the treatment of cancer | $49.8M | 71/100 | ||
8th | Developer of immunotherapeutics for the treatment of cancer and other diseases | $861M | 71/100 | ||
9th | _1545299782322.png?devicePixelRatio=2&height=30&width=30){kind=logo} Erasca 2018, San Diego (United States), Public | Developer of small molecule based therapeutics for cancer | $300M | 71/100 | |
10th |  Strand Therapeutics 2017, Cambridge (United States), Series B | Provider of platform to deliver mRNA therapeutics for multi functional treatments | $256M | 71/100 | |
747th | AbelZeta 2009, Rockville (United States), Funding Raised | Developer of T cell-based therapeutics for cancer and immunological diseases | - | 47/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on AbelZeta's competitors? Click here to see the top ones
AbelZeta's Investments and acquisitions
AbelZeta has made no investments or acquisitions yet.
Reports related to AbelZeta
Here is the latest report on AbelZeta's sector:
News related to AbelZeta
Filter this listMedia has covered AbelZeta for a total of 9 events in the last 1 year, 2 of them have been about company updates.
•
AbelZeta Pharma Receives FDA IND Clearance for Phase 1b/2 Clinical Trial of C-CAR168 in Multiple SclerosisPR Newswire•Sep 14, 2026•AbelZeta
•
AbelZeta Pharma Receives FDA Clearance for IND Application of C-CAR039 (Prizlon-cel) for Large B-cell LymphomaPR Newswire•Aug 17, 2026•AbelZeta
•
AbelZeta Pharma Receives FDA Clearance for Phase II Trial of C-CAR168 in Refractory Lupus NephritisPR Newswire•Jul 27, 2026•AbelZeta
•
AbelZeta Announces Publication in Nature Journal Highlighting Clinical Findings for an Armored Autologous GPC3 CAR-T TherapyPR Newswire•Jul 23, 2026•AbelZeta
•
AbelZeta Receives EMA PRIME Designation for C-CAR168 in Lupus Nephritis and Systemic Lupus ErythematosusPR Newswire•Jul 20, 2026•AbelZeta
•
AstraZeneca to acquire China rights for AbelZeta’s CAR-T therapyPharmaceutical Business Review•Jan 19, 2026•AbelZeta, AstraZeneca
•
AstraZeneca Acquires Modella AI to Accelerate Drug Developmentmanager magazin•Jan 14, 2026•Modella, AstraZeneca, AbelZeta
•
AbelZeta Presents New Data on C-CAR168 for Autoimmune Diseases at LUPUS 2025PR Newswire•May 23, 2025•AbelZeta
•
AbelZeta Presents Preclinical Data from Study of C-CAR168 for the Treatment of Autoimmune Diseases at ACR Convergence 2024PR Newswire•Nov 17, 2024•AbelZeta
•
AbelZeta Announces Formation of Scientific Advisory Board to Support Inflammatory and Immunological DiseasesBioSpace•Jan 03, 2024•AbelZeta
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about AbelZeta
Explore our recently published companies
- Eden Lion - France based, Unfunded company
- Edgars Friseurteam - Germany based, Unfunded company
- Eder & Heinicke Productions - Munich based, 2021 founded, Unfunded company
- Eclore Moments - Werder based, 2010 founded, Unfunded company
- EckSchnitt - Germany based, Unfunded company
- Echoev - Prato based, 2008 founded, Unfunded company
